Praziquantel (PZQ) is a drug which is used by choice to schistosomiasis treatment. Currently, it is used in malaria treatment. PZQ undergoes extensive metabolism in human body, mainly in liver, by two cytochrome P-450 isoenzymes 2B1 and 3A. As a result of these biotransformations, numerous mono- and dihydroxylated derivates in B, C and D rings are formed. Only one metabolite has been identified and described, it is 4-hydroxypraziquantel (4-OH-PZQ). So far, the metabolites out of PZQ biotransformation were obtained under the influence of Ciinnighamelle echinulata and Beauveria bassiana. There were the derivatives in position C7 and in D-ring (position is unknown).
Operational Program Digital Poland, 2014-2020, Measure 2.3: Digital accessibility and usefulness of public sector information; funds from the European Regional Development Fund and national co-financing from the state budget.
Oct 2, 2020
Feb 4, 2020
|Porównanie metabolizmu prazikwantelu in silico i in vitro||Oct 2, 2020|
Godawska, Anna Kieć-Kononowicz, Katarzyna
Latacz, Gniewomir Pękala, Elżbieta Kieć-Kononowicz, Katarzyna
Ziółkowski, Piotr Babula- Skowrońska, Danuta Kaczmarek, Małgorzata Cieśla, Agata Sadowski, Jan
Nowak, Jacek K.